China Vitamin Market Research Report 2014-2017

China is also the world’s largest export base of vitamins, mainly vitamin C, vitamin E and pantothenic calcium. In 2013, China’s export volume of vitamin C and vitamin E accounted for 55.0% and 23.7% of total export volume over the same period. In addition, the proportions of D or DL-pantothenic acid (i.e. vitamin B3 or B5) have increased to 5.7%.

China is the world’s largest production base of vitamins, with vitamin C and vitamin E as its most important products, wherein vitamin C and related products account for more than 60% of its total output and vitamin E takes up about 30%. Since 2009, influenced by the sluggish external demand and declining prices, China’s output of vitamin products has been declining sharply. In 2013, the output of various types of vitamin products in China was about 201,000 tons, down 7.4% YoY.

Chinese vitamin producers fall into two types: large integrated pharmaceutical enterprises and professional vitamin producers. In 2009-2013, large integrated pharmaceutical enterprises such as North China Pharmaceutical Co.,Ltd and Northeast Pharmaceutical Group Co.,Ltd mostly had heavy burden historically and encountered operating difficulties and development obstacles, thus their ratio of R & D investment in total revenue was less than 3%; while professional vitamin producers like NHU, Kingdomway, and Brother Enterprises Holding kept higher gross margins of their products, with R & D investment generally accounting for more than 4% of revenue.

View Complete Report @ http://www.rnrmarketresearch.com/china-vitamin-industry-report-2014-2017-market-report.html .

In recent years, the global and Chinese vitamin market has been exhibiting a monopolistic competition pattern. CSPC Pharmaceutical Group, North China Pharmaceutical, Northeast Pharmaceutical, Aland (Jiangsu) Nutraceutical, Shandong Luwei Pharmaceutical and other Chinese companies with production capacity of more than 15,000 tons, are the major suppliers in the global VC market. Zhejiang Medicine, NHU, and PKU Healthcare together shared about 50% of the global total capacity of VE. NHU, Zhejiang Medicine and Kingdomway three companies together accounted for 40%-50% of the global total capacity of VA.

Since the vitamin industry has high technical barriers, the existing major producers have already formed their own competitive advantages and the cost of quitting is high. So it is estimated that in 2014-2017, the monopolistic competition pattern in China vitamin industry will persist.

“China Vitamin Industry Report, 2014-2017″ provided by ResearchInChina covers the following:

·         China vitamin market supply and demand, import and export, competition pattern and development projections.

·         Development status, competition pattern, import and export, market prices of VC, VA, VB, VE products in China.

·         Operation, vitamin business and development prospects of 16 global and Chinese vitamin companies.

Purchase a Copy of this Report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=183545 .

Table of Contents

1 Overview of Vitamins
1.1 Definition
1.2 Classification
1.3 Global Overview

2 Development of China Vitamin Industry
2.1 Status Quo
2.2 Import and Export
2.2.1 Export
2.2.2 Import
2.3 Competition Pattern

3 China Vitamin Market Segments
3.1 VA
3.1.1 Development Status
3.1.2 Import and Export
3.1.3 Market Price
3.2 VB
3.2.1 D or DL-Pantothenic Acid (Vitamin B3 or Vitamin B5)
3.2.2 VB6
3.2.3 VB1
3.2.4 VB2
3.2.5 Choline Chloride (VB4)
3.2.6 VB12
3.3 VC
3.3.1 Development Status
3.3.2 Import and Export
3.3.3 Market Price
3.4 VE
3.4.1 Development Status
3.4.2 Import and Export
3.4.3 Market Price
3.5 Others

4 Key Enterprises
4.1 DSM
4.1.1 Profile
4.1.2 Operation
4.1.3 Vitamin Business
4.1.4 R&D
4.1.5 Business in China
4.2 BASF
4.2.1 Profile
4.2.2 Operation
4.2.3 Vitamin Business
4.2.4 Business in China
4.3 Adisseo
4.3.1 Profile
4.3.2 Vitamin Business
4.3.2 R & D
4.4 CSPC Pharmaceutical Group Limited
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Vitamin Business
4.4.5 R & D
4.5 Shandong Xinhua Pharmaceutical
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Vitamin Business
4.5.5 R & D
4.5.6 Major Clients
4.6 North China Pharmaceutical
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.5.4 Vitamin Business
4.6.5 R & D
4.6.6 Major Clients
4.7 PKU Healthcare
4.7.1 Profile
4.7.2 Operation
4.7.3 Revenue Structure
4.7.4 Vitamin Business
4.7.5 R & D
4.7.6 Major Clients
4.8 Zhejiang Medicine Co., Ltd.
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 Vitamin Business
4.8.5 R & D
4.8.6 Major Clients
4.9 Northeast Pharmaceutical
4.9.1 Profile
4.9.2 Operation
4.9.3 Revenue Structure
4.9.4 Vitamin Business
4.9.5 R & D
4.9.6 Major Clients
4.10 Hubei Guangji Pharmaceutical
4.10.1 Profile
4.10.2 Operation
4.10.3 Revenue Structure
4.10.4 Vitamin Business
4.10.5 R & D
4.10.6 Major Clients
4.11 NHU
4.11.1Profile
4.11.2 Operation
4.11.3 Revenue Structure
4.11.4 Vitamin Business
4.11.5 R & D
4.11.6 Major Clients
4.12 Brother Enterprises Holding
4.12.1 Profile
4.12.2 Operation
4.12.3 Revenue Structure
4.12.4 Vitamin Business
4.12.5 R & D
4.12.6 Major Clients
4.13 Zhejiang Hangzhou Xinfu Pharmaceutical
4.13.1 Profile
4.13.2 Operation
4.13.3 Revenue Structure
4.13.4 Vitamin Business
4.13.5 R & D
4.13.6Major Clients
4.14 Kingdomway
4.14.1 Profile
4.14.2 Operation
4.14.3 Revenue Structure
4.14.4 R & D
4.14.5 Major Clients
4.15 Henan Topfond Pharmaceutical Co.,Ltd
4.15.1 Profile
4.15.2 Operation
4.15.3 Vitamin Business
4.15.4 R & D
4.16 Xinfa Pharmaceutical
4.16.1 Profile
4.16.2 Operation

5 Forecasts and Outlook
5.1 Output and Product Mix
5.2 Competition Pattern

Explore All Market Intelligence Research Reports on Pharmaceuticals @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .